← Leaderboards
David P Aucoin
University Of Nevada Reno
$3,713,791
Attributed
$6,463,415
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2010–23$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,463,415 · 8
By mechanism
R42$1,994,739 · 1
R41$1,789,116 · 3
R33$1,103,408 · 1
R21$796,618 · 2
U54$779,534 · 1
Top collaborators
- Thomas R Kozel5 shared
- Raymond Houghton4 shared
- Syamal Raychaudhuri3 shared
- Monica E Embers2 shared
- Kathryn J Pflughoeft1 shared
Most similar at University Of Nevada Reno
Same institution · by research overlap
- Nathan Christopher Nieto$70,500
- Michael Bela Teglas$70,500
- Kathryn J Pflughoeft$115,908
Others in their field
Top investigators on “Detection”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Francis L Halzen · University Of Wisconsin-Madison$243,423,219
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- Richard A Gibbs · Baylor College Of Medicine$209,716,260
- Richard K. Wilson · Washington University$206,265,868
- Craig B Thompson · Sloan-Kettering Inst Can Research$156,512,301
Research focus
DetectionAntigensSerumDiagnosisImmunoassaySamplingMonoclonal AntibodiesInfectionDiagnosticMelioidosisIn VivoEarly DiagnosisUrineValidationLaboratoriesProteinsDiagnostic TestsPolysaccharidesPreparationSiteBloodBaseEnzyme-Linked Immunosorbent AssayLeft
Grant awards (19)
Enrichment and validation of urine and serum-specific antigens from acute Lyme disease patient samples$184,633
R21 · FY2023 · AI · contact PI
Enrichment and validation of urine and serum-specific antigens from acute Lyme disease patient samples$231,815
R21 · FY2022 · AI
Point-of-care antigen detection assay for early diagnosis of Ebola virus disease (EVD)$298,935
R41 · FY2021 · AI
Point-of-care antigen detection assay for early diagnosis of Ebola virus disease (EVD)$299,112
R41 · FY2020 · AI
Antigen Detection assay for the Diagnosis of Melioidosis$700,138
R42 · FY2016 · AI
Antigen Detection assay for the Diagnosis of Melioidosis$673,521
R42 · FY2015 · AI
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum$292,713
R41 · FY2015 · AI · contact PI
Antigen Detection assay for the Diagnosis of Melioidosis$621,080
R42 · FY2014 · AI
Target discovery and immunoassay for diagnosis of invasive aspergillosis$336,893
R33 · FY2014 · AI
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum$298,958
R41 · FY2014 · AI · contact PI
Target discovery and immunoassay for diagnosis of invasive aspergillosis$361,662
R33 · FY2013 · AI
Antigen Detection Assay for the Diagnosis of Melioidosis$299,699
R41 · FY2013 · AI
Antigenemia immunoassay for point of care dianostic melioidosis$237,957
U54 · FY2013 · AI · contact PI
Target discovery and immunoassay for diagnosis of invasive aspergillosis$404,853
R33 · FY2012 · AI
Antigen Detection Assay for the Diagnosis of Melioidosis$299,699
R41 · FY2012 · AI
Antigenemia immunoassay for point of care dianostic melioidosis$254,522
U54 · FY2012 · AI · contact PI
Antigenemia immunoassay for point of care dianostic melioidosis$287,055
U54 · FY2011 · AI · contact PI
Target discovery and immunoassay for diagnosis of invasive aspergillosis$189,820
R21 · FY2011 · AI
Target discovery and immunoassay for diagnosis of invasive aspergillosis$190,350
R21 · FY2010 · AI